Effects of Inulin on Cardiometabolic Risk Factors in Individuals Using Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA ) Medications for Weight Loss

Inclusion criteria: * Be overweight or obese (meeting any of the following criteria): 1. Obesity: BMI \>=28 kg/m²; 2. Overweight (BMI \>= 24 kg/m²) with at least one body weight-related comorbidity: obstructive sleep apnea syndrome, prediabetes, type 2 diabetes mellitus, hypertension, dyslipidemia, polycystic ovary syndrome, or non-alcoholic fatty liver disease. * Must have received GLP-1 RA drugs (Semaglutide, Liraglutide, Benaglutide, Tirzepatide, or Mazdutide) for weight-loss intervention for at least 3 months, and plan to continue using them for the next six months. * Age 18-64 years. * Consent to participate and sign the informed consent form. Exclusion criteria: * Currently using non-GLP-1 RA medications for weight-loss, or have undergone or plan to undergo weight-loss procedures within the next 4 months; * Long-term user of prebiotics or probiotics (excluding fermented dairy products such as yogurt); * Be allergic or intolerance to inulin-type substances; * Have participated in in other clinical trials within the past 3 months or are currently participating in other clinical trials; * Plan to be pregnant within the next year, are currently pregnant, or are breastfeeding; * Deemed unsuitable for participation by the investigator's judgment.